Future potential therapeutics to treat MASH

Abstract

Metabolic dysfunction-associated steatohepatitis (MASH), a progressive form of Metabolic-associated steatotic liver disease (MASLD), poses a significant global health challenge due to its association with obesity, type 2 diabetes, and cardiovascular complications. Despite its rising prevalence, effective therapies remain limited. This review highlights emerging therapeutic strategies that target key pathways involved in MASH pathogenesis, including THR-β, FXR, PPAR, GLP-1RA, FGF21, and SGLT2. In addition, novel approaches such as gene therapy (siRNA), probiotics, fecal microbiota transplantation, and stem cell therapy show promise for the treatment of MASH. Ongoing clinical trials and mechanistic insights into fibrosis, inflammation, and lipid metabolism provide hope for tailored, multi-targeted treatments. Future efforts must address safety, long-term efficacy, and non-invasive diagnostics to advance the management of MASH.